Miragen Therapeutics (NASDAQ:MGEN) released its earnings results on Thursday. The medical research company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06), Fidelity Earnings reports. Miragen Therapeutics had a negative return on equity of 85.50% and a negative net margin of 925.52%. The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.67 million.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of MGEN traded down $0.02 during midday trading on Friday, reaching $0.71. 114,900 shares of the stock were exchanged, compared to its average volume of 213,136. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $23.64 million, a P/E ratio of -0.65 and a beta of 1.37. The company’s 50 day moving average is $0.79 and its two-hundred day moving average is $1.73. Miragen Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.96.
A number of research firms have weighed in on MGEN. ValuEngine upgraded Miragen Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright began coverage on Miragen Therapeutics in a research note on Monday, August 19th. They issued a “buy” rating and a $3.00 target price on the stock. Finally, Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $11.56.
About Miragen Therapeutics
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Recommended Story: How to calculate the intrinsic value of a stock